| Drug Name |
Tamoxifen |
| Drug ID |
BADD_D02111 |
| Description |
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026]
Tamoxifen was granted FDA approval on 30 December 1977.[L7799] |
| Indications and Usage |
Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L02BA01 |
| DrugBank ID |
DB00675
|
| KEGG ID |
D08559
|
| MeSH ID |
D013629
|
| PubChem ID |
2733526
|
| TTD Drug ID |
D07KSG
|
| NDC Product Code |
Not Available |
| Synonyms |
Tamoxifen | ICI-47699 | ICI 47699 | ICI47699 | Nolvadex | Novaldex | Tamoxifen Citrate | Citrate, Tamoxifen | Tomaxithen | Zitazonium | ICI-46474 | ICI 46474 | ICI46474 | ICI-46,474 | ICI 46,474 | ICI46,474 | Soltamox |
